预约演示
更新于：2026-04-25
Lithium gamolenate
更新于：2026-04-25
概要
基本信息
药物类型 小分子化药 |
别名 Glamolec、LiGLA、Lithium-gamma linolenate + [3] |
作用方式 刺激剂 |
作用机制 Prostaglandin synthases stimulants |
在研适应症- |
非在研适应症 |
原研机构 |
在研机构- |
权益机构- |
最高研发阶段终止临床3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H30LiO2 |
InChIKeyPULYXVPPEOPWIV-HPFCUAHCSA-N |
CAS号122051-95-0 |
关联
1
项与 Lithium gamolenate 相关的临床试验NCT00612807
Adapting Marital Therapy in Older Adults With Depression
100 项与 Lithium gamolenate 相关的临床结果
登录后查看更多信息
100 项与 Lithium gamolenate 相关的转化医学
登录后查看更多信息
100 项与 Lithium gamolenate 相关的专利（医药）
登录后查看更多信息
11,522
项与 Lithium gamolenate 相关的文献（医药）2026-04-01PHYTOMEDICINE
Dingxin recipe Ⅲ ameliorates atherosclerosis through stard4-mediated regulation of hepatic lipid metabolism
Article
作者: Zhang, Yaxin ; Han, Zhouzhen ; Jia, Yuhua ; Gu, Yuyan ; He, Jieying ; Tang, Jingyu ; He, Peikun ; Liu, Xiaoyu ; Li, Zhaoyong ; Cheng, Saibo ; Zhou, Fenghua ; Jin, Yao ; Zhao, Huashan
BACKGROUND:
Atherosclerosis is the pathological basis of cardiovascular diseases. Dingxin Recipe III (DXRIII), a traditional Chinese herbal formula, has shown therapeutic effect for atherosclerosis, though its mechanisms remain unclear. This study aimed to investigate the effects and molecular mechanisms of DXRIII on atherosclerosis progression.
METHODS:
Male ApoE-/- mice were fed a high-fat diet for 12 weeks to induce atherosclerosis, followed by 12 weeks of treatment with DXRIII (7.5 or 15 g/kg/d), atorvastatin, or saline. Serum lipids, liver enzymes, aortic plaques, and hepatic lipid deposition were assessed. Transcriptomics, proteomics, and metabolomics analyses identified hepatic molecular changes. Key targets were validated by western blot, RT-qPCR, immunohistochemistry, and hepatocyte models. Molecular docking and cellular thermal shift assay assessed the direct binding of DXRIII components to target proteins. Gene overexpression and knockdown experiments were conducted in vitro and in vivo.
RESULTS:
DXRIII significantly reduced aortic plaque areas, improved lipid profiles (decreased triglycerides, total cholesterol, and low-density lipoprotein-C), and alleviated hepatic steatosis. Integrated multi-omics revealed modulation of lipid metabolism pathways, including steroid hormone biosynthesis and arachidonic acid metabolism pathways. Steroidogenic acute regulatory-related lipid transfer protein 4 (Stard4) was identified as a key target, with expression positively correlated with gamma-linolenic acid and negatively correlated with corticosterone. Direct binding between DXRIII components and Stard4 was observed. Stard4 overexpression reduced lipid accumulation, while knockdown aggravated lipid deposition and negated the effect of DXRIII. Hepatic Stard4 knockdown aggravated atherosclerosis and lipid-related genes expression (Angptl4, Apob, Soat2, Scarb1, Lepr).
CONCLUSION:
DXRIII attenuates atherosclerosis by upregulating hepatic Stard4 expression to restore lipid homeostasis and reduce lipid accumulation.
2026-04-01Journal of Nutrition Health & Aging
Distinct associations between body mass index and polyunsaturated fatty acids in dementia with Lewy Bodies and Alzheimer’s disease
Article
作者: Borda, Miguel Germán ; Chong, Joyce Ruifen ; Vik-M, Audun Osland ; Barreto, George E ; Tovar-Rios, Diego Alejandro ; Castellanos-Perilla, Nicolás ; Jaramillo-Jimenez, Alberto ; Berge, Rolf K ; Aarsland, Dag
OBJECTIVE:
We aimed to assess the association between body mass index and polyunsaturated fatty acids to determine potential links and metabolic differences between Alzheimer's disease and dementia with Lewy bodies.
METHODS:
We performed a cross-sectional study of enrolment data with 133 patients with mild AD (n = 75) and DLB (n = 58) from a Norwegian cohort study. We used linear regression models adjusting for age, sex, and diagnosis to explore the association between PUFA concentrations and BMI estimates.
RESULTS:
In DLB patients, BMI was positively associated with downstream omega-6 PUFA, including gamma-linolenic acid (GLA; β = 0.285, p = 0.012), arachidonic acid (AA; β = 0.320, p = 0.005), and adrenic acid (β = 0.303, p = 0.005). BMI was also related to increased Δ6-desaturase n-6 activity (β = 0.383, p = 0.002) and Δ6-desaturase n-3 activity (β = 0.335, p = 0.011), along with reduced elongase n-6 (β = -0.396, p = 0.002) and elongase n-3 (β = -0.376, p = 0.004), suggesting increased fatty acid turnover. No significant associations were found in the AD group.
CONCLUSIONS:
BMI in DLB patients was positively associated with elevated downstream omega-6 metabolites and desaturase and elongase activity, compatible with higher fatty‑acid turnover and systemic inflammatory state hypothesized in DLB. These findings highlight the distinct metabolic alterations across dementia subtypes that are relevant for personalized nutritional strategies in dementia care.
2025-12-31Italian Journal of Animal Science
Effects of dietary hemp co-product inclusion on laying hens performances and on egg nutritional and functional profile
作者: Skřivan, M. ; Englmaierová, M. ; Petrosillo, E. ; Lanzoni, D. ; Baldi, A. ; Skřivanová, V. ; Giromini, C. ; Marchetti, L. ; Bontempo, V. ; Rebucci, R.
Farm to Fork strategy aims to guide the agri-sector to sustainable food system.Hemp co-products are featured by an interesting nutritional and functional profile.The 9% inclusion of the hemp co-product improved the performance of laying hens and the nutritional and functional profile of eggs.
1
项与 Lithium gamolenate 相关的新闻（医药）
100 项与 Lithium gamolenate 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 胰腺癌 | 临床3期 | 英国 | 2001-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用